相关实验视频

Updated: May 4, 2026

Serum and Plasma Copy Number Detection Using Real-time PCR

Serum and Plasma Copy Number Detection Using Real-time PCR

Published on: December 15, 2017

在亚洲患有转移性割抗性前列腺癌的亚洲患者中使用Olaparib Plus和阿比拉:PROpel子组分析

Mototsugu Oya¹, Jae Young Joung², Ji Youl Lee³

¹Keio University Hospital, Tokyo, Japan.

|March 18, 2025

概括

第一线olaparib加上abiraterone显著改善了亚洲患者转移性割抵抗性前列腺癌 (mCRPC) 的无进展生存率 (rPFS). 与全球人口相比,这种组合显示出一致的疗效和安全性.

科学领域:

在瘤学瘤学.
临床试验临床试验
前列腺癌研究研究前列腺癌

背景情况:

转移性割抵抗性前列腺癌 (mCRPC) 需要有效的第一线治疗.
在PROpel试验中,在mCRPC患者中研究了olaparib加上abiraterone.
以前的全球数据显示,这种组合有好处.

研究的目的:

报告PROpel试验中亚洲亚群的疗效,安全性和患者报告的结果.
评估olaparib加上abiraterone作为亚洲mCRPC患者的一线治疗.

主要方法:

第三阶段,随机化,双盲试验 (NCT03732820).
133名亚洲患有mCRPC的患者随机分配给olaparib + abiraterone或安慰剂 + abiraterone.
主要终点:由研究人员评估的无进展放射性生存率 (rPFS);关键次要终点:整体生存率 (OS).

主要成果:

在亚洲患者中,中位数的RPFS为27.6个月 (olaparib + abiraterone) 和19.3个月 (安慰剂 + abiraterone) (HR 0.55).
中位数OS没有达到 (olaparib + abiraterone) 与43.7个月 (安慰剂 + abiraterone) (HR 0.59) 相比.
亚洲人群的安全概况与全球人口一致.

结论:

在亚洲mCRPC患者中,olaparib加上abiraterone显示出显著的RPFS益处.
结果与全球PROpel试验的结果一致.
这种组合是一种有价值的第一线治疗选择,用于亚洲患者的mCRPC.

关键词:

亚洲的亚洲人亚洲人的亚洲人一个是abiraterone.转移性割抵抗性前列腺癌这就是Olaparib.没有进展的生存率.

更多相关视频

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

Focal Laser Ablation of Prostate Cancer: An Office Procedure

Focal Laser Ablation of Prostate Cancer: An Office Procedure

Published on: March 30, 2021

相关概念视频

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

Treatment Resistant Cancers

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...

Cancer Survival Analysis

Cancer Survival Analysis

Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...